News

Article

Zolbetuximab-clzb Receives FDA Approval for Treatment of Advanced Gastric and GEJ Adenocarcinoma

Key Takeaways

  • Zolbetuximab-clzb is approved for HER2-negative gastric/GEJ adenocarcinoma with CLDN18.2-positive tumors.
  • Phase 3 SPOTLIGHT and GLOW trials met their primary end point of progression-free survival.
SHOW MORE

Zolbetuximab is the first approved CLDN18.2-targeted treatment for gastric and gastroesophageal junction adenocarcinoma.

Zolbetuximab-clzb (Vyloy; Astellas Pharma Inc) was granted FDA approval for the treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative (HER2–) gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive. The decision is based on results from the phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03462719) trials which both met their primary end point of progression-free survival.1,2

fda approval gastric cancer

Image Credit: © Crystal light - stock.adobe.com

According to the American Cancer Society, there will be approximately 27,000 new stomach cancer diagnosis in 2024. Gastric and gastroesophageal junction (GEJ) adenocarcinomas make up about 90% to 95% of all stomach cancers that develop from gland cells in the mucosa of the stomach. Patients with locally advanced, metastatic, or HER2– negative disease typically have worse outcomes.3,4

Zolbetuximab-clzb is a cytolytic antibody that targets CLDN18.2, a novel therapeutic target in gastrointestinal malignancies, that affects nearly 38% of patients screened in the trials. CLDN18.2 positivity was defined as ≥75% of tumor cells showing moderate to strong membranous CLDN18 immunohistochemical staining, which was determined using the CLDN18 (43-14A) RxDx Assay (Ventana; Roche).5,6

In the SPOTLIGHT trial, the researchers evaluated zolbetuximab-clzb in combination with oxaliplatin (Eloxatin; Sanofi-Aventus), leucovorin, and fluorouracil (Tolak; Hill Dermaceuticals Inc) (mFOLFOX6) compared with placebo and mFOLFOX6. The GLOW study investigated zolbetuximab-clzb plus capecitabine (Xeloda; Genetech) and oxaliplatin (CAPOX) compared with placebo and oxaliplatin. The trials had a primary end point of PFS and a secondary end point of overall survival, which were met in both. The most common treatment-emergent adverse events associated with zolbetuximab-clzb were nausea, vomiting, and decreased appetite.5

"While there have been advances in the first-line treatment of locally advanced unresectable and metastatic gastric and GEJ cancers in the last several years, there is still a tremendous unmet need among our patients,” said Samuel J. Klempner, MD, associate professor at Harvard Medical School, medical oncologist at Massachusetts General Hospital, Boston, in a press release. “The approval of [zolbetuximab-clzb], based on the pivotal Phase 3 SPOTLIGHT and GLOW trials, brings forward a novel biomarker and new therapy for patients whose tumors are CLDN18.2 positive, and for those on the frontlines of treatment decision-making."5

The FDA’s decision makes zolbetuximab-clzb the first and only CLDN18.2-targeted treatment for adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.5

REFERENCES
1. A phase 3 efficacy, safety and tolerability study of zolbetuximab (experimental drug) plus mfolfox6 chemotherapy compared to placebo plus mfolfox6 as treatment for gastric and gastroesophageal junction (gej) cancer (spotlight). ClinicalTrials.gov Identifier: NCT03504397. Updated October 8, 2024. Accessed October 18, 2024. https://clinicaltrials.gov/study/NCT03504397
2. A study of the combination of ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab for the first-line treatment of participants with chronic lymphocytic leukemia (cll)/​small lymphocytic lymphoma (sll) (glow). ClinicalTrials.gov Identifier: NCT03462719. Updated October 10, 2024. Accessed October 18, 2024. https://clinicaltrials.gov/study/NCT03462719
3. What is stomach cancer? American Cancer Society. January 22, 2021. Accessed October 18, 2024. https://www.cancer.org/cancer/types/stomach-cancer/about/what-is-stomach-cancer.html
4. Key statistics about stomach cancer. American Cancer Society. January 19, 2024. Accessed October 18, 2024. https://www.cancer.org/cancer/types/stomach-cancer/about/key-statistics.html
5. Claudin-18.2 emerges as a novel therapeutic target in gi malignancies. OncLive. May 24, 2023. Accessed October 18, 2024. https://www.onclive.com/view/claudin-18-2-emerges-as-a-novel-therapeutic-target-in-gi-malignancies
6. Astellas' vyloy™ (zolbetuximab-clzb) approved by u.s. fda for treatment of advanced gastric and gej cancer. Astellas. October 18, 2024. Accessed October 18, 2024. https://newsroom.astellas.us/2024-10-18-Astellas-VYLOY-TM-zolbetuximab-clzb-Approved-by-U-S-FDA-for-Treatment-of-Advanced-Gastric-and-GEJ-Cancer
Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought